Lead Scientists In Japan's First iPS Clinical Trials Urges Low Expectations
This article was originally published in PharmAsia News
Japan may have cleared the world's first clinical trials using iPS cells for treatment, but the research head of the studies cautioned against great expectations.
You may also be interested in...
HBW Executive Decisions: HELP Endorses Hahn, Industry Award For AHPA's McGuffin, CHPA, Herbalife Hires
CHPA adds Allgaier to head development, relations; Vetere joins Herbalife as VP, CIO; Hahn's FDA commissioner nomination clears HELP committee; and AHPA's McGuffin recognized as 2019 Industry Leader.
Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.
Tech Companies Grappling With A Brave New World Of Regulations While Developing Digital-Health Products
Software firms interested in the digital-health arena are engaging US FDA more and bolstering their regulatory credentials to navigate an unfamiliar regulatory landscape, industry experts tell Medtech Insight.